# LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT06472479** · NA · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 66 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** LCAR-M61S cells preparation
- **BIOLOGICAL:** LCAR-M61D cells preparation

## Key facts

- **NCT ID:** NCT06472479
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2028-08-22
- **Final completion:** 2029-10-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472479, "LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06472479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*